Skip to main content
Top
Published in: BMC Ophthalmology 1/2007

Open Access 01-12-2007 | Research article

Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration

Authors: Hamid Ahmadieh, Ramin Taei, Masoud Soheilian, Mohammad Riazi-Esfahani, Reza Karkhaneh, Alireza Lashay, Mohsen Azarmina, Mohammad Hossein Dehghan, Siamak Moradian

Published in: BMC Ophthalmology | Issue 1/2007

Login to get access

Abstract

Background

To evaluate the efficacy of triple therapy consisting of single-session photodynamic therapy (PDT), intravitreal bevacizumab (IVB) and intravitreal triamcinolone (IVT) as initial pulse therapy followed by repeat intravitreal bevacizumab injections for maintenance treatment in neovascular age-related macular degeneration (AMD).

Methods

In a prospective interventional case series, patients with subfoveal choroidal neovascularization (CNV) secondary to AMD underwent pulse therapy with single-session PDT according to the standard protocol followed by 1.25 mg IVB and 2 mg IVT 48 hours later. Best corrected visual acuity (BCVA) was assessed and optical coherence tomography (OCT) and fluorescein angiography (FA) were performed prior to treatment. BCVA and OCT measurements were repeated at 6 week intervals and FA was obtained after 12 weeks and when necessary thereafter. Repeat injections of IVB were performed based on fluorescein angiographic evidence of CNV leakage.

Results

This series included 17 eyes of 17 patients with mean age of 67.6 ± 7.2 years. Mean follow up duration was 50.4 ± 15.5 weeks. Mean BCVA prior to treatment was 0.74 ± 0.33 logMAR which improved to 0.52 ± 0.36 logMAR after 12 weeks (P = 0.012) and 0.41 ± 0.38 logMAR after 24 weeks (P = 0.001). Mean pretreatment central macular thickness (CMT) was 395 ± 181μ which was significantly reduced to 217 ± 69μ (P = 0.005), 231 ± 79μ (P = 0.028) and 221 ± 87μ (P = 0.05) six, twelve and twenty-four weeks after initial treatment respectively. Visual acuity improvement and CMT reduction was maintained during the follow-up period. IVB injections were repeated once, twice and three times in 10, 7 and 2 eyes at a mean interval of 20.2 ± 10.1, 19 ± 13.7 and 15 ± 1.4 weeks after initial therapy, respectively.

Conclusion

Initial pulse triple therapy consisting of single-session PDT combined with IVB and IVT improves vision and reduces CMT in neovascular AMD. Repeat IVB injections maintain the visual gain from the initial combination therapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Treatment of Age- Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age- related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials- TAP report 1. Arch Ophthalmol. 1999, 117: 1329-1345.CrossRef Treatment of Age- Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age- related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials- TAP report 1. Arch Ophthalmol. 1999, 117: 1329-1345.CrossRef
2.
go back to reference Treatment of Age- Related Macular Degeneration with Photodynamic Therapy (TAP)Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age- related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials- TAP report 2. Arch Ophthalmol. 2001, 119: 198-207. Treatment of Age- Related Macular Degeneration with Photodynamic Therapy (TAP)Study Group: Photodynamic therapy of subfoveal choroidal neovascularization in age- related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials- TAP report 2. Arch Ophthalmol. 2001, 119: 198-207.
3.
go back to reference Verteporfin in Photodynamic Therapy (VIP) Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two- year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization- Verteporfin in Photodynamic Therapy Report 2. Am J Ophthalmol. 2001, 131: 541-560. 10.1016/S0002-9394(01)00967-9.CrossRef Verteporfin in Photodynamic Therapy (VIP) Study Group: Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two- year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization- Verteporfin in Photodynamic Therapy Report 2. Am J Ophthalmol. 2001, 131: 541-560. 10.1016/S0002-9394(01)00967-9.CrossRef
4.
go back to reference Schlotzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U: Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol. 2002, 240: 748-757.CrossRefPubMed Schlotzer-Schrehardt U, Viestenz A, Naumann GO, Laqua H, Michels S, Schmidt-Erfurth U: Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol. 2002, 240: 748-757.CrossRefPubMed
5.
go back to reference Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H: Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002, 43: 830-841.PubMed Schmidt-Erfurth U, Michels S, Barbazetto I, Laqua H: Photodynamic effects on choroidal neovascularization and physiological choroid. Invest Ophthalmol Vis Sci. 2002, 43: 830-841.PubMed
6.
go back to reference Michels S, Schmidt-Erfurth U: Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci. 2003, 44: 2147-2154. 10.1167/iovs.02-0604.CrossRefPubMed Michels S, Schmidt-Erfurth U: Sequence of early vascular events after photodynamic therapy. Invest Ophthalmol Vis Sci. 2003, 44: 2147-2154. 10.1167/iovs.02-0604.CrossRefPubMed
7.
go back to reference Schmidt-Erfurth U, Niemeyer M, Geitzenauer W, Michels S: Time course and morphology of vascular effects associated with photodynamic therapy. Ophthalmology. 2005, 112: 2061-2069. 10.1016/j.ophtha.2005.09.007.CrossRefPubMed Schmidt-Erfurth U, Niemeyer M, Geitzenauer W, Michels S: Time course and morphology of vascular effects associated with photodynamic therapy. Ophthalmology. 2005, 112: 2061-2069. 10.1016/j.ophtha.2005.09.007.CrossRefPubMed
8.
go back to reference Wang YS, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P: Inhibitory effects of triamcinolone acetonide on bFGF – induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol. 2002, 240: 42-48.CrossRefPubMed Wang YS, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P: Inhibitory effects of triamcinolone acetonide on bFGF – induced migration and tube formation in choroidal microvascular endothelial cells. Graefes Arch Clin Exp Ophthalmol. 2002, 240: 42-48.CrossRefPubMed
9.
go back to reference Danis RP, Ciulla TA, Pratt LM, Anliker W: Intravitreal triamcinolone acetonide in exudative age- related macular degeneration. Retina. 2000, 20: 244-250. 10.1097/00006982-200005000-00003.CrossRefPubMed Danis RP, Ciulla TA, Pratt LM, Anliker W: Intravitreal triamcinolone acetonide in exudative age- related macular degeneration. Retina. 2000, 20: 244-250. 10.1097/00006982-200005000-00003.CrossRefPubMed
10.
go back to reference Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W, Mitchell P, Billson F: A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol. 2003, 121: 667-673. 10.1001/archopht.121.5.667.CrossRefPubMed Gillies MC, Simpson JM, Luo W, Penfold P, Hunyor AB, Chua W, Mitchell P, Billson F: A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results. Arch Ophthalmol. 2003, 121: 667-673. 10.1001/archopht.121.5.667.CrossRefPubMed
11.
go back to reference Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF: Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol. 2004, 122: 218-222. 10.1001/archopht.122.2.218.CrossRefPubMed Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF: Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol. 2004, 122: 218-222. 10.1001/archopht.122.2.218.CrossRefPubMed
12.
go back to reference Ramezani AR, Ahmadieh H, Tabatabaie H: Intravitreal triamcinolone reinjection for refractory diabetic macular edema. Korean J Ophthalmol. 2006, 20: 156-161.CrossRefPubMedPubMedCentral Ramezani AR, Ahmadieh H, Tabatabaie H: Intravitreal triamcinolone reinjection for refractory diabetic macular edema. Korean J Ophthalmol. 2006, 20: 156-161.CrossRefPubMedPubMedCentral
13.
go back to reference Rechtman E, Danis RP, Pratt LM, Haries A: Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in age related macular degeneration. Br J Ophthalmol. 2004, 88: 344-347. 10.1136/bjo.2003.027177.CrossRefPubMedPubMedCentral Rechtman E, Danis RP, Pratt LM, Haries A: Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in age related macular degeneration. Br J Ophthalmol. 2004, 88: 344-347. 10.1136/bjo.2003.027177.CrossRefPubMedPubMedCentral
14.
go back to reference Spaide RF, Sorenson J, Maranan L: Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005, 112: 301-304. 10.1016/j.ophtha.2004.08.012.CrossRefPubMed Spaide RF, Sorenson J, Maranan L: Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology. 2005, 112: 301-304. 10.1016/j.ophtha.2004.08.012.CrossRefPubMed
15.
go back to reference Augustin AJ, Schmidt-Erfurth U: Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006, 113: 14-21. 10.1016/j.ophtha.2005.09.002.CrossRefPubMed Augustin AJ, Schmidt-Erfurth U: Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology. 2006, 113: 14-21. 10.1016/j.ophtha.2005.09.002.CrossRefPubMed
16.
go back to reference Augustin AJ, Schmidt-Erfurth U: Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age- related macular degeneration. Am J Ophthalmol. 2006, 141: 638-645. 10.1016/j.ajo.2005.11.058.CrossRefPubMed Augustin AJ, Schmidt-Erfurth U: Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age- related macular degeneration. Am J Ophthalmol. 2006, 141: 638-645. 10.1016/j.ajo.2005.11.058.CrossRefPubMed
17.
go back to reference Ruiz-Moreno JMA, Montero JA, Barile S, Zarbin MA: Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration. Retina. 2006, 26: 602-612. 10.1097/00006982-200607000-00003.PubMed Ruiz-Moreno JMA, Montero JA, Barile S, Zarbin MA: Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration. Retina. 2006, 26: 602-612. 10.1097/00006982-200607000-00003.PubMed
18.
go back to reference Chan WM, Lai TYY, Wong AL, Tong JP, Liu DTL, Lam DSC: Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularization in age related macular degeneration: a comparative study. Br J Ophthalmol. 2006, 90: 337-341. 10.1136/bjo.2005.081299.CrossRefPubMedPubMedCentral Chan WM, Lai TYY, Wong AL, Tong JP, Liu DTL, Lam DSC: Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularization in age related macular degeneration: a comparative study. Br J Ophthalmol. 2006, 90: 337-341. 10.1136/bjo.2005.081299.CrossRefPubMedPubMedCentral
19.
go back to reference Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ: Intravitreal bevacizumab (Avastin) for neovascular age- related macular degeneration. Ophthalmology. 2006, 113: 363-372. 10.1016/j.ophtha.2005.11.019.CrossRefPubMed Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ: Intravitreal bevacizumab (Avastin) for neovascular age- related macular degeneration. Ophthalmology. 2006, 113: 363-372. 10.1016/j.ophtha.2005.11.019.CrossRefPubMed
20.
go back to reference Aggio FB, Melo GB, Hofling-Lima AL, Farah ME: Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration. Acta Ophthalmologica Scandinavica. 2006, 84: 831-833. 10.1111/j.1600-0420.2006.00764.x.CrossRefPubMed Aggio FB, Melo GB, Hofling-Lima AL, Farah ME: Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration. Acta Ophthalmologica Scandinavica. 2006, 84: 831-833. 10.1111/j.1600-0420.2006.00764.x.CrossRefPubMed
21.
go back to reference Dhalla MS, Shah GK, Blinder KJ, Ryan EH, Mittra RA, Tewari A: Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina. 2006, 26: 988-993. 10.1097/01.iae.0000247164.70376.91.CrossRefPubMed Dhalla MS, Shah GK, Blinder KJ, Ryan EH, Mittra RA, Tewari A: Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina. 2006, 26: 988-993. 10.1097/01.iae.0000247164.70376.91.CrossRefPubMed
22.
go back to reference Costa RA, Jorge R, Calucci D, Melo LA, Cardillo JA, Scott IU: Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Greafes Arch Clin Exp Ophthalmol. 2007, Feb 28: DOI 10.1007/s00417-007-0557-x, Costa RA, Jorge R, Calucci D, Melo LA, Cardillo JA, Scott IU: Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Greafes Arch Clin Exp Ophthalmol. 2007, Feb 28: DOI 10.1007/s00417-007-0557-x,
23.
go back to reference Augustin AJ, Puls S, Offermann I: Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007, 27: 133-140. 10.1097/IAE.0b013e3180323de7.CrossRefPubMed Augustin AJ, Puls S, Offermann I: Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina. 2007, 27: 133-140. 10.1097/IAE.0b013e3180323de7.CrossRefPubMed
24.
go back to reference Peyman GA, Kazi AA, Unal M, Khoobehi B, Yoneya S, Mori K, Moshfeghi DM: Problems with and pitfalls of photodynamic therapy. Ophthalmology. 2000, 107: 29-35. 10.1016/S0161-6420(99)00012-3.CrossRefPubMed Peyman GA, Kazi AA, Unal M, Khoobehi B, Yoneya S, Mori K, Moshfeghi DM: Problems with and pitfalls of photodynamic therapy. Ophthalmology. 2000, 107: 29-35. 10.1016/S0161-6420(99)00012-3.CrossRefPubMed
25.
go back to reference Reinke MH, Canakis C, Husain D, Michaud N, Flotte TJ, Gragoudas ES, Miller JW: Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology. 1999, 106: 1915-1923. 10.1016/S0161-6420(99)90401-3.CrossRefPubMed Reinke MH, Canakis C, Husain D, Michaud N, Flotte TJ, Gragoudas ES, Miller JW: Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology. 1999, 106: 1915-1923. 10.1016/S0161-6420(99)90401-3.CrossRefPubMed
26.
go back to reference Schmidt-Erfurth U, Schlotzer-Schrehardt U, Cursiefen C, Michels S, Beckendorf A, Naumann GO: Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium – derived factor. Invest Ophthalmol Vis Sci. 2003, 44: 4473-4480. 10.1167/iovs.02-1115.CrossRefPubMed Schmidt-Erfurth U, Schlotzer-Schrehardt U, Cursiefen C, Michels S, Beckendorf A, Naumann GO: Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium – derived factor. Invest Ophthalmol Vis Sci. 2003, 44: 4473-4480. 10.1167/iovs.02-1115.CrossRefPubMed
27.
go back to reference Obata R, Inoue Yuji, Iriyama A, Takahashi H, Tamaki Y, Yanagi Y: Triamcinolone acetonide suppresses early proangiogenic response in RPE cells after photodynamic therapy in vitro. Br J Ophthalmol. 2007, 91: 100-104. 10.1136/bjo.2006.098004.CrossRefPubMed Obata R, Inoue Yuji, Iriyama A, Takahashi H, Tamaki Y, Yanagi Y: Triamcinolone acetonide suppresses early proangiogenic response in RPE cells after photodynamic therapy in vitro. Br J Ophthalmol. 2007, 91: 100-104. 10.1136/bjo.2006.098004.CrossRefPubMed
Metadata
Title
Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration
Authors
Hamid Ahmadieh
Ramin Taei
Masoud Soheilian
Mohammad Riazi-Esfahani
Reza Karkhaneh
Alireza Lashay
Mohsen Azarmina
Mohammad Hossein Dehghan
Siamak Moradian
Publication date
01-12-2007
Publisher
BioMed Central
Published in
BMC Ophthalmology / Issue 1/2007
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/1471-2415-7-10

Other articles of this Issue 1/2007

BMC Ophthalmology 1/2007 Go to the issue